Abstract
Insulin replacement therapy for diabetes mellitus seeks to minimise excursions in blood glucose concentration above or below the therapeutic range (hyper- or hypoglycaemia). To mitigate acute and chronic risks of such excursions, glucose-responsive insulin-delivery technologies have long been sought for clinical application in type 1 and long-standing type 2 diabetes mellitus. Such ‘smart’ systems or insulin analogues seek to provide hormonal activity proportional to blood glucose levels without external monitoring. This review highlights three broad strategies to co-optimise mean glycaemic control and time in range: (1) coupling of continuous glucose monitoring (CGM) to delivery devices (algorithm-based ‘closed-loop’ systems); (2) glucose-responsive polymer encapsulation of insulin; and (3) mechanism-based hormone modifications. Innovations span control algorithms for CGM-based insulin-delivery systems, glucose-responsive polymer matrices, bio-inspired design based on insulin’s conformational switch mechanism upon insulin receptor engagement, and glucose-responsive modifications of new insulin analogues. In each case, innovations in insulin chemistry and formulation may enhance clinical outcomes. Prospects are discussed for intrinsic glucose-responsive insulin analogues containing a reversible switch (regulating bioavailability or conformation) that can be activated by glucose at high concentrations.
Graphical abstract
Similar content being viewed by others
Introduction
Insulin replacement therapy (IRT) is essential for the treatment of type 1 diabetes mellitus and often required by patients with late-stage type 2 diabetes. Advances in diabetes technologies have been broadly motivated by the aim to link optimisation of IRT (including individualised glycaemic goals in type 2 diabetes [1, 2]) and healthcare outcomes [3,4,5,6,7,8]. During a typical 24 h period, patients on insulin therapy often exhibit episodes of hyperglycaemia or hypoglycaemia [9], despite individualised dosing regimens [10, 11] and the broad use of engineered basal and rapid-acting insulin analogues [12,13,14]. Indeed, glycaemic excursions outside the narrow blood glucose range classified as normoglycaemia (4.4–6.7 mmol/l) [15] are frequent despite strict adherence to dietary and lifestyle recommendations [16, 17]. These challenges have motivated innovation in ancillary technologies: formulation chemistry, protein engineering, glucose-sensing technologies and delivery devices [18, 19]. Integrating IRT with engineered mechanisms of feedback (whether at the level of protein, cell or device) represents a critical current frontier of innovation, with the overarching goal of fewer hyperglycaemic excursions and reduced time in hypoglycaemia (i.e. increased time in range [TIR]). TIR is a major issue, ever-present in the daily life of an individual with type 1 diabetes [20, 21] and in a subset of those with type 2 diabetes [22].
In this review we outline a range of glucose-responsive (‘smart’) approaches to control TIR and discuss the prospects for mechanism-based molecular design of intrinsic glucose-responsive insulin (GRI) analogues [23]. Such delivery systems or insulin analogues seek to optimise TIR by the combined approaches of increased engineering controls to deliver insulin therapeutics and the molecular design of new chemical entities. Like endogenous beta cells, such systems (broadly designated GRIs) would provide insulin activity proportionate to the metabolic state. Accordingly, the GRI concept has attracted the attention of the research community [24,25,26,27] and funders [28, 29] alike.
GRIs may be broadly classified as: (1) algorithm-based mechanical GRI systems (closed-loop delivery systems as an ‘artificial pancreas’) based on continuous glucose monitoring (CGM)-coupled insulin pumps [30]; (2) polymer-based systems, wherein insulin is encapsulated within a glucose-responsive polymeric matrix-based vesicle or hydrogel [31]; or (3) molecular GRI analogue systems, which involve the introduction of a glucose-sensitive motif to the insulin molecule or its formulation that, in either case, confers glucose-responsive changes to bioavailability or hormonal activity [32] (Fig. 1). We highlight potential synergies among these technologies as molecular GRIs may, in principle, be delivered via a closed-loop system (for further review, please see a related article in this special series by Boughton and Hovorka [33]). Cell-based therapies, which provide biological feedback regulation [34, 35], are beyond the scope of this review.
Mechanical systems
Closed-loop systems
Mechanical GRI systems [36] integrate: (1) CGM to provide real-time measurement of interstitial glucose concentration; (2) an insulin pump receiving CGM input; and (3) a control algorithm specifying the appropriate dose of insulin for minute-by-minute s.c. injection [11, 37, 38]. Although these systems promise to improve 24 h glycaemic control in diverse patient populations (including adults, adolescents and children), CGM-based measurements of interstitial glucose concentrations lag by ~20 min behind changes in blood glucose levels, complicating prediction of future glycaemic trends. Reliable prediction is important because a ‘rapid-acting’ insulin analogue (once injected) may require 20–40 min for absorption and, once in the blood stream, may exert biological effects lasting 3–4 h [39]. The robustness of current predictive algorithms is likely to be enhanced by development of ‘ultra-fast’ pump insulin analogue formulations [40], such as Fiasp (Novo Nordisk) [41, 42], ultra-rapid lispro (URLi; known as Lyumjev in Europe; Eli Lilly) [43, 44], and respective reformulations of prandial analogues insulin, including insulin aspart (ProB28 → Asp) and insulin lispro (ProB28 → Lys and LysB29 → Pro) [45,46,47]. The progress of CGM along with automated real-time insulin titration and bolus calculators, has enabled initial regulatory approval of mechanical GRI systems [11].
Dual-hormone pumps
To prevent or treat hypoglycaemia more effectively, bihormonal pumps have been developed to provide either insulin or its counter-regulatory hormone glucagon [48,49,50,51,52,53]. Dual-hormone algorithms trigger s.c. injections of a stabilised glucagon formulation based on trends in CGM readings predicting an impending hypoglycaemic excursion, thereby maintaining blood glucose levels within range more efficiently than conventional CGM-coupled insulin pumps [54, 55]; the extent of advantage and its clinical impact have been the subject of debate. Fibrillation-resistant formulations of glucagon or glucagon analogues would be required for practical bihormonal systems [56].
Insulin stability in closed-loop systems
Ultra-miniaturisation of sensors and improved accuracy of pumps [36, 57, 58] have encouraged reconsideration of i.p. delivery of insulin via i.p. infusion devices [59, 60]. Implanted refillable pumps [61] have promised ultra-rapid pharmacokinetic dosing profiles of insulin with first-pass hepatic signalling in the portal circulation. These advantageous features have stimulated interest in novel i.p.-compatible insulin analogue formulations; desiderata include insulins with even more rapid onset of activity, shorter duration and greater formulation stability compared with the insulin therapeutics currently on the market.
Despite the above theoretical advantages and the convenience of long-term i.p. reservoirs of insulin (up to 3 months), catheter occlusion [62] remains a concern that has limited the feasibility of such systems in otherwise encouraging clinical trials [63]. Occlusions are often mediated by immunogenic and proinflammatory insulin-derived amyloid fibrils [64, 65]. Insulin instability and fibrillation can also occur within the pump reservoir to inactivate the hormone and provide seeds for further cycles of fibrillation.
Risk of insulin degradation in i.p. systems might be mitigated through design and development of ultra-stable, fibrillation-resistant analogues. Examples are provided by single-chain insulins (SCIs) containing a foreshortened C domain [66] and by two-chain insulin analogues containing an engineered non-canonical disulfide bridge between A- and B-chains [67,68,69] (Fig. 2). The altered topology (connectivity) of such analogues appears incompatible with cross-β assembly, the canonical core structure of an amyloid [70,71,72]. Their topologies may, in principle, alter the signalling properties of the hormone. Insertion of non-canonical cystine B4–A10 (Fig. 2b), for example, is associated with anomalously prolonged duration of activity of insulin upon intravenous bolus injection in rat studies [67], an unfavourable property of a pump insulin, the safety of which relies on fast-on/fast-off pharmacodynamics. Clinical data are not available.
Polymer-based GRI systems
Polymer-based technologies exploit sequestration of native or derivatised insulin within a matrix suitable for s.c. injection by directly integrating glucose-responsive components into delivery systems [73, 74]. The matrix, in principle, senses the glucose concentration and releases a proportional amount of insulin. Three classes of glucose-sensitive motifs have enabled such feedback: (1) glucose-binding proteins, a class that includes lectins, like concanavalin A (ConA); (2) glucose oxidase, an enzyme that catalyses oxidation of glucose to gluconic acid with release of a proton (hence lowering the pH); and (3) boronate-based chemistries, exemplified by phenylboronic acid (PBA; see below), which form reversible ester linkages with diol-containing molecules [75], including glucose [76]. In addition to these categories, an innovative recent technology envisions endogenous biological systems (e.g., the mannose receptor and even components of the erythrocyte) as a ‘smart’ matrix-based insulin delivery system [77, 78].
Insulin–lectin complexes
More than 40 years ago, Brownlee and Cerami pioneered a model GRI system: glycosylated insulin complexed with ConA [24, 79]. This complex was designed to sequester insulin in the s.c. space during normoglycaemia and release the hormone during hyperglycaemia via competition with ambient glucose molecules (Fig. 3b). Although the strategy was successful in vitro, its competitive set point was above the range of typical hyperglycaemic concentrations [79]. ConA’s immunogenicity and mitogenicity might limit clinical translation [80, 81].
Glucose-responsive polymers
Advances in materials science have enabled design of diverse candidate polymer-based GRI systems. These were based on initial observations of Lorand and Edwards [75] that boronic acids react reversibly with vicinal (1,2-) diols (like those that occur naturally in carbohydrates and catechol); their reaction yields boronate esters. Norrild and Eggert first provided NMR evidence that binding of PBA to d-glucose is primarily mediated by the α-d -glucofuranose conformer (Fig. 4) [76]. Subsequently, Wang’s group [82, 83] described a mechanism/mechanisms of binding between diols and boronic acids (reviewed by Joop A. Peters in relation to monosaccharides [84]). Such systems envisaged encapsulation of insulin within polymeric matrices to form a ‘smart’ s.c. depot. The set points of chemical equilibrium-based glucose-recognition technologies (relative to enzyme- or protein-based schemes) may be more amenable to optimisation than ConA systems were found to be.
Polymer-based GRIs can, in principle, employ a variety of encapsulation chemistries, including polyethylene glycol (PEF), poly(N-vinyl-pyrrolidone) and succinyl-amidophenyl-glucopyranoside [31, 74, 85]. Whereas the matrices are impermeable to insulin during normoglycaemic or hypoglycaemic conditions, their permeability may increase as a result of physical changes that cause swelling or increased water solubility of the polymer in response to an increase in interstitial glucose concentration. Examples include matrices co-derivatised with PBA, other boronic acids [86,87,88] and dot-immobilised glucose ester-based crosslinks [74, 85, 89].
Immobilised glucose-binding proteins and enzymes may also be integrated with glucose-modified polymers [77, 90]. Of particular interest, glucose oxidase has been encapsulated in matrices that are chemically sensitive to H2O2, hypoxia or decreases in local pH. Unlike PBA and non-enzymatic glucose-binding-protein-based technologies, polymeric matrices in glucose oxidase-based systems exploit its catalytic activity to increase the polymer’s water permeability and, so, regulate hormone release [91, 92] (for review, see Wang et al [73]).
Polymer-based GRI technologies are challenged by limited particle stability [93, 94], lag times and suboptimal insulin-response rates leading to hyperglycaemic or hypoglycaemic excursions. Addressing these limitations has encountered a catch-22: sensitising matrices to hyperglycaemia, for example, can limit their ability to attenuate insulin release at low glucose concentrations. The latter problem can be exacerbated by matrix degradation, in principle raising the risk of severe hypoglycaemic episodes in patients due to bolus over-delivery [95, 96].
Intrinsic GRI systems
Intrinsic (or unimolecular) GRIs define a novel class of analogues wherein the modified hormone itself confers glucose-dependent activity or bioavailability. Initial candidate technologies relied on sequestration of active insulin hormone within the s.c. space or within the bloodstream (as inactive complexes) with enhanced release or activation only during hyperglycaemia. Recent bio-inspired advances exploit specific endogenous features of the s.c. space, potential hormone-carrier proteins or cellular clearance systems. Although these elegant strategies remain in the early stages of development, their simplicity, convenience and potential cost-effectiveness make them an attractive target of ongoing research. Because standard insulin products are becoming a commodity in the pharmaceutical industry, clinical introduction of chemically modified insulins that are glucose responsive will likely require detailed analysis of cost-effectiveness despite their elegance.
Insulin fusion proteins
A pioneering approach employed an insulin–glucose oxidase fusion molecule [97]. A cysteine-based linkage was broken as the enzyme oxidised glucose. Although proof of principle was obtained in vitro, the low Km of the enzyme for glucose led to liberation of the hormone under hypoglycaemic, as well as hyperglycaemic conditions [97]. In addition, release of H2O2 by glucose oxidase (as a byproduct of glucose oxidation) and generation of reactive oxygen species (ROS) could cause tissue injury. In a complementary approach, glucose oxidase-dependent changes in s.c. pH were exploited to modulate the solubility (and, hence, rate of absorption) of insulin glargine, the isoelectric point-shifted active component of Lantus (Sanofi) [98]. Because this basal analogue is insoluble at neutral pH but soluble under acidic conditions, glucose oxidase-mediated acidification (via production of gluconic acid), in principle, enhances bioavailability [99] (Fig. 3c). Although in vitro and pilot animal studies appear promising, clinical data has not yet been obtained [100].
Biology-inspired GRI systems
An attractive frontier of GRI engineering takes advantage of an endogenous biological system, ‘hijacked’ in its native form to provide an active component of a glucose-dependent regulatory scheme. Such an approach was developed by Merck, based on competitive clearance of a saccharide-modified insulin by the endogenous mannose receptor [101, 102]. The saccharide adduct presented terminal mannose moieties and so provided a substrate for clearance by the ubiquitous mannose receptor system. The essential idea envisioned rapid clearance of the modified insulin under conditions of hypoglycaemia but slow clearance under conditions of hyperglycaemia due to low-affinity binding of glucose to (and, hence, competition at) the mannose receptor. The glucose-dependent differences in rates of clearance, although not large, were sufficient to provide partial protection from hypoglycaemia relative to the same dose of an unmodified insulin. Although animal-based and pilot clinical studies were pursued, this approach is no longer under development. These challenges to create a modified insulin with an improved therapeutic index that enables tighter glycaemic control with a reduced risk for hypoglycaemia, as well as the challenges of translating in vivo animal models and data for application in humans, highlight the importance of developing better in silico GRI modelling in the developmental pipeline [23, 103,104,105].
PBA-modified insulin derivatives
PBA is a diol-binding element that is able to sense carbohydrates [106,107,108]. A PBA-modified insulin derivative was first described as a potential intrinsic GRI by Hoeg-Jensen et al [32]. This work established that PBA could be coupled to the insulin B29 position without affecting its biological activity, in turn enabling the analogue to bind diol-containing sequestering agents (Fig. 3). The investigators further demonstrated that a modified insulin carrying both a PBA and a polyol group attached to the LysB29 sidechain could form high molecular weight multimeric complexes that dissociate under control by d-sorbitol or d-glucose (Fig. 3e) [109, 110]. A sidechain glutamic acid linker was required for in vitro activity, as is the case for insulin degludec, a second-generation basal acylated insulin [111]. To our knowledge, no in vivo results have been described.
Novel use of a PBA-based GRI was described by Chou and colleagues [112] who employed an acylated insulin analogue (insulin detemir) in which myristic acid was coupled onto lysine (LysB29) to mediate binding to serum albumin and, so, provide a long-lived circulating depot of insulin. The hydrocarbon acyl tag was further derivatised with PBA so that its affinity for albumin might be glucose responsive. The essential idea thus envisioned albumin as a glucose-dependent carrier, similar, in spirit, to the reported use of erythrocyte membranes as glucose-dependent carriers [77, 113]. Although this goal was not achieved in vitro with this analogue (i.e. the albumin-binding properties of the analogues were not glucose-dependent), several such candidate GRI analogues exhibited glucose-responsive biological activity in a peritoneal glucose-infusion assay in mice [73].
In a similar manner to the above, Jensen and colleagues [114] took advantage of albumin binding as a plasma depot to demonstrate novel GRI activity acceleration, which was mediated by aldehyde-responsive capture of released insulin. The strategy biased for glucose reactivity over fructose by virtue of aldehyde capture based on the increased reactivity of acyclic glucosyl aldehyde over fructosyl ketone and the fact that fasting glucose concentrations are about >1000-fold greater than those of fructose (Fig. 4) [114]. In the same study [114], in glucose clamp models, some insulin analogues demonstrated GRI activity, but their in vitro hydrolysis rates were >6 h, suggesting that lag time might be an issue.
Glucose-regulated conformational switches
A reversible conformational cycle between active and inactive states of insulin may, in principle, be regulated by a ligand, such as glucose (Fig. 1b). A new avenue for molecular GRI design was inspired by crystallographic and cryogenic electron microscopy (cryo-EM) studies of insulin bound to fragments of the insulin receptor [115, 116], including the intact ectodomain [117, 118]. Such studies revealed a major change in the conformation of insulin on receptor binding in which the hormone ‘opens’ with detachment of the C-terminal B-chain segment; this enables intimate contact between the N-terminal A-chain α-helix and the receptor complex [117, 118].
It may be possible to exploit the mechanism of insulin–insulin receptor binding and signalling to design a glucose-dependent conformational switch, such that binding of the modified insulin to the insulin receptor is impaired under hypoglycaemic conditions. A glucose-displaceable bridge between a glucose-binding element attached to one position in the insulin molecule and an internal ligand (such as a diol or saccharide) may, in principle, be placed at any pair of sites, such that the ‘closed state’ is inactive and the ‘open state’ is active. Proof of principle was recently provided in studies of a fructose-responsive insulin (FRI), in which meta-fluoro-PBA was attached to the A-chain N-terminus, and an aromatic diol group was attached to the ε-amino group of LysB28 to provide an internal tether between the A- and B-chains (see ‘open, active’ form in Fig. 1b) [119]. Whilst the baseline activity of this analogue was low, near-native activity (as assessed in studies of the liver-derived cell line HepG2) was restored by 50 mmol/l fructose, but not by 50 mmol/l glucose [119].
The binding preference of PBA and its derivatives for fructose (relative to glucose) reflects their respective conformational equilibria and, in particular, the subpopulation of conformers displaying cis-1,2-diols that have hydroxyl groups that are oriented syn-periplanar (same side) for joint presentation to the boronic acid (Fig. 4c) [108]. Such alignment depends on the conformational equilibrium of a monosaccharide, as is observed in the β-d-fructofuranose form (Fig. 4c). Because the analogous conformation of glucose (α-d-glucofuranose; Fig. 4c) is >100-fold less populated compared with β-d-fructofuranose at equilibrium in solution [84, 120], binding of PBAs to fructose is significantly favoured. Improved glucose-binding elements will be required to extend the FRI proof-of-principle results to obtain bona fide GRIs. A chemical diversity of candidate boronate-based glucose sensors has been described [73, 82, 121,122,123,124], as well as non-boronate-based chemistries [125,126,127]. In addition, the above FRI’s bridge between the A-chain N-terminus and B-chain C-terminus follows naturally from the hormone’s mechanism of insulin receptor binding [116], but a wide variety of bridges might exhibit analogous glucose-responsive properties. Such design options promise an opportunity to co-optimise other GRI molecular features, including stability and immunogenicity.
To define potential non-canonical pairs of conformational switch sites suitable for GRI design, DiMarchi and colleagues [128] undertook a systematic survey of fourth disulfide bridges in an insulin analogue (des-[B29,B30]-LysB28-insulin; ‘DesDi’ [129]). Whereas previous efforts to engineer additional disulfide bridges into insulin were motivated by stability [67,68,69], this study’s emphasis was on differences in insulin receptor binding on closure of the fourth bridge. Six such pairs of putative switch sites were identified based on this functional criterion (Fig. 5). These pairs are distant in the native structure of insulin; formation of the engineered disulfide bridge (forced by selective chemical tactics) presumably distorts the conformation of the hormone, including its insulin receptor-binding surface. Predicted distances between the unpaired cysteines in the framework of native insulin (T state) are given in Fig. 5 and reported as interatomic distances.
To visualise these novel analogues on closure of the non-native disulfide bridge, we undertook molecular modelling of the six constrained insulin analogues based on distance-geometry and restrained molecular dynamics. A baseline set of restraints was provided by prior NMR analysis of engineered insulin monomers [130, 131]. Of such fourth disulfide bridges, only cystine A0–B26 (Fig. 6c) could be accommodated within a native-like protein conformation (Fig. 7). A glucose-displaceable tether between amino acid residues A0 and B26 would, thus, be analogous to the fructose-regulated switch described above [119].
In the other five cases, formation of the fourth disulfide seems to require partial unfolding of the protein, perturbing one or more α-helical elements (Fig. 6a, b, d–f); these distortions are incompatible with the structure of the primary insulin-binding site in the insulin receptor. For example, imposing cystines A8–B10 or A14–B10 in our modelling (Fig. 6d, e) distorted the central B-chain α-helix and N-terminal A-chain α-helix, key insulin receptor-binding elements [116]. Displacement of such aberrant bridges by glucose would presumably relieve the distortion and, so, restore activity. A rational path towards switchable intrinsic GRIs, based on strained disulfide engineering, was envisaged by DiMarchi and colleagues [128]. It would be of future interest to probe the structures and stabilities of these strained analogues, whether they contain cystine or reversible glucose-displaceable tethers. We anticipate that the set point for glucose displacement would be modulated by the degree of conformational strain.
Clinical significance and conclusions
The centennial of the discovery of insulin marks a time of continuing innovation in insulin technologies. Even as the events leading to insulin discovery in Toronto in 1921 are celebrated as a landmark in molecular medicine, a comprehensive history recognises not only the contributions of Frederick Banting, Charles Best, James B. Collip and John J. R. Macleod, but also the key insights and advances made by others in the preceding five decades, beginning with Oskar Minkowski and Joseph von Mering (Germany) and continuing with Étienne Lancereaux (France), Nicolae C. Paulescu (Romania) and Israel Kleiner (USA) [132].
The present review highlights a vibrant frontier of insulin technologies. Whereas closed-loop systems have recently become a clinical reality [133,134,135], polymer-based and intrinsic GRIs promise to enhance the safety and efficacy of IRT. In addition to the elegance of the associated chemistries and macromolecular structures, ongoing research has a compelling clinical motivation: to enhance the health and quality of life of patients with type 1 diabetes and of patients with type 2 diabetes refractory to oral therapy—and with less burden on patients [136]. To bridge the valley between basic science and clinical applications, in silico simulations of animal physiology and human patients are likely to provide key guidance [23, 103,104,105].
All three classes of GRI technologies considered here, namely closed-loop delivery (as an ‘artificial pancreas’), polymer-based systems and molecular GRI analogue systems, seek to achieve optimal TIR. Standard IRT faces a trade-off: on the one hand, strict glycaemic control has been shown to retard or prevent microvascular complications in type 1 diabetes [6] and is likely to be beneficial in early stages of type 2 diabetes [137,138,139] but, on the other hand, aggressive glycaemic targets increase the acute and long-term risks of hypoglycaemia [10, 140,141,142,143]. Whereas CGM pump-based GRIs presently employ the most mature component technologies, recent innovations in matrix-based and unimolecular GRIs suggest promising routes towards safe and effective approximation of pancreatic beta cell function. We anticipate continuing progress in the coming years to reduce the burden of diabetes. Given the balance of price and access to new therapeutics (especially derivatised insulin analogues [144]) and the high human and economic costs of long-term diabetes complications, such innovative technologies are likely to be cost-effective when considering the integrated impact on society.
Abbreviations
- CGM:
-
Continuous glucose monitoring
- ConA:
-
Concanavalin A
- FRI:
-
Fructose-responsive insulin
- GRI:
-
Glucose-responsive insulin
- IRT:
-
Insulin replacement therapy
- PBA:
-
Phenylboronic acid
- TIR:
-
Time in range
References
Ismail-Beigi F (2011) Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial - clinical implications. Clin Chem 57:261–263. https://doi.org/10.1373/clinchem.2010.148288
Ismail-Beigi F (2012) Glycemic management of type 2 diabetes mellitus. N Engl J Med 366(14):1319–1327. https://doi.org/10.1056/NEJMcp1013127
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986. https://doi.org/10.1056/nejm199309303291401
Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643–2653. https://doi.org/10.1056/NEJMoa052187
Stolar M (2010) Glycemic control and complications in type 2 diabetes mellitus. Am J Med 123(3):S3–S11. https://doi.org/10.1016/j.amjmed.2009.12.004
Nathan DM, Group DER (2014) The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 37(1):9–16
Hayward RA, Reaven PD, Wiitala WL et al (2015) Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372(23):2197–2206. https://doi.org/10.1056/NEJMoa1414266
Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM, DCCT/EDIC Research Group (2019) Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC study. Diabetes Care 42(7):1284–1289. https://doi.org/10.2337/dc18-1613
Campbell MD, Walker M, Bracken RM et al (2015) Insulin therapy and dietary adjustments to normalize glycemia and prevent nocturnal hypoglycemia after evening exercise in type 1 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care 3(1):e000085. https://doi.org/10.1136/bmjdrc-2015-000085
Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S (2011) Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154(8):554–559. https://doi.org/10.1059/0003-4819-154-8-201104190-00007
Nimri R, Battelino T, Laffel LM et al (2020) Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes. Nat Med 26(9):1380–1384. https://doi.org/10.1038/s41591-020-1045-7
Vajo Z, Fawcett J, Duckworth WC (2001) Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 22:706–717. https://doi.org/10.1210/edrv.22.5.0442
Hartman I (2008) Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 6(2):54–67. https://doi.org/10.3121/cmr.2008.793
Tibaldi JM (2014) Evolution of insulin: from human to analog. Am J Med 127(10 Suppl):S25–S38. https://doi.org/10.1016/j.amjmed.2014.07.005
Petznick A (2011) Insulin management of type 2 diabetes mellitus. Am Fam Physician 84(2):183–190
Dandona P (2017) Minimizing glycemic fluctuations in patients with type 2 diabetes: approaches and importance. Diabetes Techn Therap 19(9):498–506. https://doi.org/10.1089/dia.2016.0372
Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F (2019) A view beyond HbA1c: role of continuous glucose monitoring. Diabetes Ther 10(3):853–863. https://doi.org/10.1007/s13300-019-0619-1
Grant AK, Golden L (2019) Technological advancements in the management of type 2 diabetes. Curr Diab Rep 19(12):163. https://doi.org/10.1007/s11892-019-1278-3
Zimmerman C, Albanese-O’Neill A, Haller MJ (2019) Advances in type 1 diabetes technology over the last decade. Eur Endocrin 15(2):70–76. https://doi.org/10.17925/ee.2019.15.2.70
Yu S, Fu AZ, Engel SS, Shankar RR, Radican L (2016) Association between hypoglycemia risk and hemoglobin A1C in patients with type 2 diabetes mellitus. Curr Med Res Opin 32(8):1409–1416. https://doi.org/10.1080/03007995.2016.1176017
Martyn-Nemeth P, Quinn L, Penckofer S, Park C, Hofer V, Burke L (2017) Fear of hypoglycemia: influence on glycemic variability and self-management behavior in young adults with type 1 diabetes. J Diabetes Complicat 31(4):735–741. https://doi.org/10.1016/j.jdiacomp.2016.12.015
Lipska KJ, Warton EM, Huang ES et al (2013) HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care 36(11):3535–3542. https://doi.org/10.2337/dc13-0610
Bakh NA, Cortinas AB, Weiss MA et al (2017) Glucose-responsive insulin by molecular and physical design. Nat Chem 9(10):937. https://doi.org/10.1038/nchem.2857
Brownlee M, Cerami A (1979) A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin. Science 206(4423):1190–1191. https://doi.org/10.1126/science.505005
Zaykov AN, Mayer JP, DiMarchi RD (2016) Pursuit of a perfect insulin. Nat Rev Drug Discov 15(6):425–439. https://doi.org/10.1038/nrd.2015.36
Hoeg-Jensen T (2020) Glucose-sensitive insulin. Mol Metab 101107. https://doi.org/10.1016/j.molmet.2020.101107
Disotuar MM, Chen D, Lin N-P, Chou DH-C (2020) Glucose-responsive insulin through bioconjugation approaches. J Diabetes Sci Technol 14(2):198–203. https://doi.org/10.1177/1932296819854105
NIDDK (2011) Advances and emerging opportunities in diabetes research: a Strategic Planning report of the Diabetes Mellitus Interagency Coordinating Committee. Available from: www.niddk.nih.gov/about-niddk/strategic-plans-reports/advances-emerging-opportunities-diabetes-research-strategic-planning-report. Accessed 31 Jan 2021
Insel RA, Deecher DC, Brewer J (2012) Juvenile Diabetes Research Foundation: mission, strategy, and priorities. Diabetes 61(1):30–35
Halvorson M, Carpenter S, Kaiserman K, Kaufman FR (2007) A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump. J Ped 150(1):103–105. e101. https://doi.org/10.1016/j.jpeds.2006.08.069
Ravaine V, Ancla C, Catargi B (2008) Chemically controlled closed-loop insulin delivery. J Control Release 132(1):2–11. https://doi.org/10.1016/j.jconrel.2008.08.009
Hoeg-Jensen T, Ridderberg S, Havelund S et al (2005) Insulins with built-in glucose sensors for glucose responsive insulin release. J Pept Sci 11(6):339–346. https://doi.org/10.1002/psc.624
Boughton CK, Hovorka R (2021) New closed-loop insulin systems. Diabetologia. https://doi.org/10.1007/s00125-021-05391-w
Vegas AJ, Veiseh O, Gürtler M et al (2016) Long-term glycemic control using polymer-encapsulated human stem cell–derived beta cells in immune-competent mice. Nat Med 22(3):306. https://doi.org/10.1038/nm.4030
Chen Z, Hu Q, Gu Z (2018) Leveraging engineering of cells for drug delivery. Acc Chem Res 51(3):668–677. https://doi.org/10.1021/acs.accounts.7b00526
Thabit H, Hovorka R (2016) Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia 59(9):1795–1805. https://doi.org/10.1007/s00125-016-4022-4
Garg SK, Weinzimer SA, Tamborlane WV et al (2017) Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Techn Therap 19(3):155–163. https://doi.org/10.1089/dia.2016.0421
Hanaire H, Franc S, Borot S et al (2020) Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise. Diabetes Obes Metab 22(3):324–334. https://doi.org/10.1111/dom.13898
Genuth SM (1972) Metabolic clearance of insulin in man. Diabetes 21(10):1003–1012. https://doi.org/10.2337/diab.21.10.1003
Breton M, Farret A, Bruttomesso D et al (2012) Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 61(9):2230–2237. https://doi.org/10.2337/db11-1445
Cypryk K, Wyrębska-Niewęgłowska A (2018) New faster-acting insulin Fiasp®—do we need a new meal-time insulin? Clin Diabetol 7(6):282–286
Majdpour D, Yale J-F, Legault L et al (2020) 10-novel fully automated Fiasp-plus-pramlintide artificial pancreas for type 1 diabetes: randomized controlled trial. Can J Diabetes 44(7):S4–S5. https://doi.org/10.1016/j.jcjd.2020.08.014
Linnebjerg H, Zhang Q, LaBell E et al (2020) Pharmacokinetics and glucodynamics of ultra rapid Lispro (URLi) versus Humalog® (Lispro) in younger adults and elderly patients with type 1 diabetes mellitus: a randomised controlled trial. Clin Pharm 59(12):1589–1599. https://doi.org/10.1007/s40262-020-00903-0
Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM (2020) Randomized double-blind clinical trial comparing ultra rapid lispro with Lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D. Diabetes Care 43(12):2991–2998. https://doi.org/10.2337/dc19-2550
Lougheed WD, Zinman B, Strack TR et al (1997) Stability of insulin lispro in insulin infusion systems. Diabetes Care 20:1061–1065. https://doi.org/10.2337/diacare.20.7.1061
Mudaliar SR, Lindberg FA, Joyce M et al (1999) Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin. Diabetes Care 22:1501–1506. https://doi.org/10.2337/diacare.22.9.1501
Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H (2005) Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 113:435–443. https://doi.org/10.1055/s-2005-865806
Bakhtiani PA, Caputo N, Castle JR et al (2014) A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. J Diabetes Sci Technol 9(1):17–23
Jacobs PG, El Youssef J, Reddy R et al (2016) Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab 18(11):1110–1119. https://doi.org/10.1111/dom.12707
Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R (2015) Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endo 3(1):17–26. https://doi.org/10.1016/S2213-8587(14)70226-8
Haidar A, Legault L, Matteau-Pelletier L et al (2015) Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endo 3(8):595–604. https://doi.org/10.1016/S2213-8587(15)00141-2
Haidar A (2019) Insulin-and-glucagon artificial pancreas versus insulin-alone artificial pancreas: a short review. Diabetes Spectrum 32(3):215–221. https://doi.org/10.2337/ds18-0097
Castle JR, El Youssef J, Wilson LM et al (2018) Randomized outpatient trial of single-and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care 41(7):1471–1477. https://doi.org/10.2337/dc18-0228
Blauw H, Keith-Hynes P, Koops R, DeVries JH (2016) A review of safety and design requirements of the artificial pancreas. Ann Biomed Eng 44(11):3158–3172. https://doi.org/10.1007/s10439-016-1679-2
El-Khatib FH, Balliro C, Hillard MA et al (2016) Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet 389(10067):369–380
Jackson MA, Caputo N, Castle JR, David LL, Roberts CT, Ward WK (2012) Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas. Curr Diabetes Rep 12(6):705–710. https://doi.org/10.1007/s11892-012-0320-5
Ribet F, Stemme G, Roxhed N (2017) Ultra-miniaturization of a planar amperometric sensor targeting continuous intradermal glucose monitoring. Biosensors Bioelectr 90:577–583. https://doi.org/10.1016/j.bios.2016.10.007
Graf A, McAuley SA, Sims C et al (2016) Moving toward a unified platform for insulin delivery and sensing of inputs relevant to an artificial pancreas. J Diabetes Sci Tech 1932296816682762
Schade DS, Eaton RP, Friedman JE, Spencer WJ (1980) Normalization of plasma insulin profiles with intraperitoneal insulin in diabetic man. Diabetologia 19:35–39. https://doi.org/10.1007/BF00258308
Schade DS, Eaton P (1980) The peritoneum—a potential insulin delivery route for a mechanical pancreas. Diabetes Care 3(2):229–234. https://doi.org/10.2337/diacare.3.2.229
Irsigler K, Kritz H, Hagmüller G et al (1981) Long-term continuous intraperitoneal insulin infusion with an implanted remote-controlled insulin infusion device. Diabetes 30(12):1072–1075. https://doi.org/10.2337/diab.30.12.1072
Renard E, Boutleau S, Jacques-Apostol D et al (1996) Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility. Diabetes Care 19:812–817. https://doi.org/10.2337/diacare.19.8.812
Saudek CD, Duckworth WC, Giobbie-Hurder A et al (1996) Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. JAMA 276:1322–1327. https://doi.org/10.1001/jama.1996.03540160044031
Bally L, Thabit H, Hovorka R (2017) Finding the right route for insulin delivery–an overview of implantable pump therapy. Expert Opin Drug Deliv 14(9):1103–1111
Jeandidier N, Boivin S, Sapin R et al (1995) Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38:577–584. https://doi.org/10.1007/BF00400727
Hua QX, Nakagawa SH, Jia W et al (2008) Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications. J Biol Chem 283:14703–14716. https://doi.org/10.1074/jbc.M800313200
Vinther TN, Norrman M, Ribel U et al (2013) Insulin analog with additional disulfide bond has increased stability and preserved activity. Protein Sci 22(3):296–305. https://doi.org/10.1002/pro.2211
Wu F, Mayer JP, Gelfanov VM, Liu F, DiMarchi RD (2017) Synthesis of four-disulfide insulin analogs via sequential disulfide bond formation. J Org Chem 82(7):3506–3512. https://doi.org/10.1021/acs.joc.6b03078
Xiong X, Blakely A, Karra P et al (2020) Novel four-disulfide insulin analog with high aggregation stability and potency. Chem Sci 11(1):195–200. https://doi.org/10.1039/C9SC04555D
Tycko R (2011) Solid-state NMR studies of amyloid fibril structure. Annu Rev Phys Chem 62:279–299. https://doi.org/10.1146/annurev-physchem-032210-103539
Tycko R, Ishii Y (2003) Constraints on supramolecular structure in amyloid fibrils from two-dimensional solid-state NMR spectroscopy with uniform isotopic labeling. J Am Chem Soc 125:6606–6607. https://doi.org/10.1021/ja0342042
Dobson CM (2003) Protein folding and misfolding. Nature 426:884–890. https://doi.org/10.1038/nature02261
Wang J, Wang Z, Yu J, Kahkoska AR, Buse JB, Gu Z (2020) Glucose-responsive insulin and delivery systems: innovation and translation. Adv Mat 32(13):1902004. https://doi.org/10.1002/adma.201902004
Shen D, Yu H, Wang L et al (2020) Recent progress in design and preparation of glucose-responsive insulin delivery systems. J Control Release 321:236–258. https://doi.org/10.1016/j.jconrel.2020.02.014
Lorand JP, Edwards JO (1959) Polyol complexes and structure of the benzeneboronate ion. J Org Chem 24(6):769–774. https://doi.org/10.1021/jo01088a011
Norrild JC, Eggert H (1995) Evidence for mono-and bisdentate boronate complexes of glucose in the furanose form. Application of 1JC-C coupling constants as a structural probe. J Am Chem Soc 117(5):1479–1484. https://doi.org/10.1021/ja00110a003
Wang C, Ye Y, Sun W et al (2017) Red blood cells for glucose-responsive insulin delivery. Adv Mat 29(18):1606617. https://doi.org/10.1002/adma.201606617
Yang J, Wang F, Lu Y et al (2019) Recent advance of erythrocyte-mimicking nanovehicles: from bench to bedside. J Control Release 314:81–91. https://doi.org/10.1016/j.jconrel.2019.10.032
Brownlee M, Cerami A (1983) Glycosylated insulin complexed to concanavalin A. Biochemical basis for a closed-loop insulin delivery system. Diabetes 32(6):499–504. https://doi.org/10.2337/diab.32.6.499
Ballerstadt R, Evans C, McNichols R, Gowda A (2006) Concanavalin A for in vivo glucose sensing: a biotoxicity review. Biosens Bioelectron 22(2):275–284. https://doi.org/10.1016/j.bios.2006.01.008
Coutinho A, Larsson EL, Grönvik KO, Andersson J (1979) Studies on T lymphocyte activation II. The target cells for concanavalin A-induced growth factors. Eur J Immun 9(8):587–592. https://doi.org/10.1002/eji.1830090803
Karnati VV, Gao X, Gao S et al (2002) A glucose-selective fluorescence sensor based on boronicacid-diol recognition. Bioorg Med Chem Lett 12(23):3373–3377. https://doi.org/10.1016/S0960-894X(02)00767-9
Fang H, Kaur G, Wang B (2004) Progress in boronic acid-based fluorescent glucose sensors. J Fluoresc 14(5):481–489. https://doi.org/10.1023/B:JOFL.0000039336.51399.3b
Peters JA (2014) Interactions between boric acid derivatives and saccharides in aqueous media: structures and stabilities of resulting esters. Coord Chem Rev 268:1–22. https://doi.org/10.1016/j.ccr.2014.01.016
Zhao R, Lu Z, Yang J, Zhang L, Li Y, Zhang X (2020) Drug delivery system in the treatment of diabetes mellitus. Frontiers Bioengin Biotechn 8:880
Jin X, Zhang X, Wu Z et al (2009) Amphiphilic random glycopolymer based on phenylboronic acid: synthesis, characterization, and potential as glucose-sensitive matrix. Biomacromol 10(6):1337–1345. https://doi.org/10.1021/bm8010006
Wang Y, Huang F, Sun Y, Gao M, Chai Z (2017) Development of shell cross-linked nanoparticles based on boronic acid-related reactions for self-regulated insulin delivery. J Biomater Sci Polym Ed 28(1):93–106. https://doi.org/10.1080/09205063.2016.1246289
Wang H, Yi J, Yu Y, Zhou S (2017) NIR upconversion fluorescence glucose sensing and glucose-responsive insulin release of carbon dot-immobilized hybrid microgels at physiological pH. Nanoscale 9(2):509–516. https://doi.org/10.1039/C6NR07818D
Dong Y, Wang W, Veiseh O et al (2016) Injectable and glucose-responsive hydrogels based on boronic acid–glucose complexation. Langmuir 32(34):8743–8747. https://doi.org/10.1021/acs.langmuir.5b04755
Zion TC, Tsang HH, Ying JY (2003) Glucose-sensitive nanoparticles for controlled insulin delivery. Available from: https://dspace.mit.edu/handle/1721.1/3783. Accessed 31 Jan 2021
Li X, Fu M, Wu J et al (2017) pH-sensitive peptide hydrogel for glucose-responsive insulin delivery. Acta Biomater 51:294–303. https://doi.org/10.1016/j.actbio.2017.01.016
Anirudhan T, Nair AS, Nair SS (2016) Enzyme coated beta-cyclodextrin for effective adsorption and glucose-responsive closed-loop insulin delivery. Int J Biol Macromol 91:818–827. https://doi.org/10.1016/j.ijbiomac.2016.06.028
Shi D, Ran M, Zhang L et al (2016) Fabrication of biobased polyelectrolyte capsules and their application for glucose-triggered insulin delivery. ACS Appl Mater Interfaces 8(22):13688–13697. https://doi.org/10.1021/acsami.6b02121
Taylor MJ, Chauhan KP, Sahota TS (2020) Gels for constant and smart delivery of insulin. Brit J Diabetes 20(1):41–51. https://doi.org/10.15277/bjd.2020.248
Gu Z, Dang TT, Ma M et al (2013) Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery. ACS Nano 7(8):6758–6766. https://doi.org/10.1021/nn401617u
Yesilyurt V, Webber MJ, Appel EA, Godwin C, Langer R, Anderson DG (2016) Injectable self-healing glucose-responsive hydrogels with pH-regulated mechanical properties. Adv Mater 28(1):86–91. https://doi.org/10.1002/adma.201502902
Ito Y, Imanishi Y (1994) Protein device for glucose-sensitive release of insulin. Design and synthesis of a protein device that releases insulin in response to glucose concentration. Bioconjug Chem 5(1):84–87. https://doi.org/10.1021/bc00025a011
Hilgenfeld R, Seipke G, Berchtold H, Owens DR (2014) The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 74(8):911–927. https://doi.org/10.1007/s40265-014-0226-4
Gillies PS, Figgitt DP, Lamb HM (2000) Insulin glargine. Drugs 59(2):253–260. https://doi.org/10.2165/00003495-200059020-00009
Kashyap N, Steiner SS, Pohl R inventors; Biodel, Inc., assignee. Insulin formulations for insulin release as a function of tissue glucose levels. US patent application 2009/0,175,840 A1. 9 Jul 2009
Kaarsholm NC, Lin S, Yan L et al (2018) Engineering glucose responsiveness into insulin. Diabetes 67(2):299–308. https://doi.org/10.2337/db17-0577
Yang R, Wu M, Lin S et al (2018) A glucose-responsive insulin therapy protects animals against hypoglycemia. JCI Insight 3(1):e97476. https://doi.org/10.1172/jci.insight.97476
Yang JF, Gong X, Bakh NA et al (2020) Connecting rodent and human pharmacokinetic models for the design and translation of glucose-responsive insulin. Diabetes 69(8):1815–1826. https://doi.org/10.2337/db19-0879
Taylor SI, DiMarchi RD (2020) Smarter modeling to enable a smarter insulin. Diabetes 69(8):1608–1610. https://doi.org/10.2337/dbi20-0011
Visser SA, Kandala B, Fancourt C, Krug AW, Cho CR (2020) A model-informed drug discovery and development strategy for the novel glucose-responsive insulin MK-2640 enabled rapid decision making. Clin Pharm Therap 107(6):1296–1311. https://doi.org/10.1002/cpt.1729
Friedman S, Pizer R (1975) Mechanism of the complexation of phenylboronic acid with oxalic acid. Reaction which requires ligand donor atom protonation. J Am Chem Soc 97(21):6059–6062. https://doi.org/10.1021/ja00854a018
Springsteen G, Wang B (2002) A detailed examination of boronic acid–diol complexation. Tetrahedron 58(26):5291–5300. https://doi.org/10.1016/S0040-4020(02)00489-1
Wu X, Li Z, Chen X-X, Fossey JS, James TD, Jiang Y-B (2013) Selective sensing of saccharides using simple boronic acids and their aggregates. Chem Soc Rev 42(20):8032–8048. https://doi.org/10.1039/c3cs60148j
Hoeg-Jensen T, Havelund S, Markussen J inventors; Novo Nordisk A/S, assignee. Glucose-dependent insulins. US patent 7,317,000 B2. 8 Jan 2008
Hoeg-Jensen T, Havelund S, Markussen J, Ostergaard S, Ridderberg S, Balschmidt P, Schaffer L, Jonassen I inventors; Novo Nordisk A/S, assignee. Glucose dependent release of insulin from glucose sensing insulin derivatives. US patent 7,316,999 B2. 8 Jan 2008
Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U (2012) Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 29(8):2104–2114. https://doi.org/10.1007/s11095-012-0739-z
Chou DH-C, Webber MJ, Tang BC et al (2015) Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc Natl Acad Sci 112(8):2401–2406. https://doi.org/10.1073/pnas.1424684112
Wang J, Yu J, Zhang Y et al (2019) Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. Proc Natl Acad Sci 116(22):10744–10748. https://doi.org/10.1073/pnas.1901967116
Jensen KJ, Mannerstedt K, Mishra NK et al (2020) An aldehyde responsive, cleavable linker for glucose responsive Insulins. Chemistry. https://doi.org/10.1002/chem.202004878
Menting JG, Whittaker J, Margetts MB et al (2013) How insulin engages its primary binding site on the insulin receptor. Nature 493(7431):241–245. https://doi.org/10.1038/nature11781
Menting JG, Yang Y, Chan SJ et al (2014) Protective hinge in insulin opens to enable its receptor engagement. Proc Natl Acad Sci 111(33):E3395–E3404
Scapin G, Dandey VP, Zhang Z et al (2018) Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis. Nature 556(7699):122–125. https://doi.org/10.1038/nature26153
Weis F, Menting JG, Margetts MB et al (2018) The signalling conformation of the insulin receptor ectodomain. Nat Commun 9(1):4420. https://doi.org/10.1038/s41467-018-06826-6
Weiss M inventor; Case Western Reserve University, assignee. Insulin analogues with a glucose-regulated conformational switch. US patent 10,584,156 B2. 10 Mar 2020
Angyal SJ (1984) The composition of reducing sugars in solution. In: Tipson RS, Horton D (eds) Advances in carbohydrate chemistry and biochemistry, vol 42. Elsevier, Amsterdam, pp 15–68
Bérubé M, Dowlut M, Hall DG (2008) Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: structure and selectivity of complex formation. J Org Chem 73(17):6471–6479. https://doi.org/10.1021/jo800788s
Pal A, Bérubé M, Hall DG (2010) Design, synthesis, and screening of a library of peptidyl bis (boroxoles) as oligosaccharide receptors in water: identification of a receptor for the tumor marker TF-antigen disaccharide. Angew Chem Int Ed 49(8):1492–1495. https://doi.org/10.1002/anie.200906620
Sharma B, Bugga P, Madison LR et al (2016) Bisboronic acids for selective, physiologically relevant direct glucose sensing with surface-enhanced Raman spectroscopy. J Am Chem Soc 138(42):13952–13959. https://doi.org/10.1021/jacs.6b07331
Bian Z, Liu A, Li Y et al (2020) Boronic acid sensors with double recognition sites: a review. Analyst 145(3):719–744. https://doi.org/10.1039/C9AN00741E
Sun X, James TD (2015) Glucose sensing in supramolecular chemistry. Chem Rev 115(15):8001–8037. https://doi.org/10.1021/cr500562m
Davis AP (2020) Biomimetic carbohydrate recognition. Chem Soc Rev 49(9):2531–2545. https://doi.org/10.1039/C9CS00391F
Tromans RA, Samanta SK, Chapman AM, Davis AP (2020) Selective glucose sensing in complex media using a biomimetic receptor. Chem Sci 11(12):3223–3227. https://doi.org/10.1039/C9SC05406E
Brunel FM, Mayer JP, Gelfanov VM et al (2019) A disulfide scan of insulin by [3+ 1] methodology exhibits site-specific influence on bioactivity. ACS Chem Biol 14(8):1829–1835. https://doi.org/10.1021/acschembio.9b00420
Zaykov AN, Mayer JP, Gelfanov VM, Dimarchi RD (2014) Chemical synthesis of insulin analogs through a novel precursor. ACS Chem Biol 9(3):683–691. https://doi.org/10.1021/cb400792s
Hua QX, Hu SQ, Frank BH et al (1996) Mapping the functional surface of insulin by design: structure and function of a novel A-chain analogue. J Mol Biol 264:390–403. https://doi.org/10.1006/jmbi.1996.0648
Hua QX, Xu B, Huang K et al (2009) Enhancing the activity of insulin by stereospecific unfolding. Conformational life cycle of insulin and its evolutionary origins. J Biol Chem 284:14586–14596. https://doi.org/10.1074/jbc.M900085200
Bliss M (2103) The discovery of insulin: the twenty-fifth anniversary edition. University of Chicago Press, Chicago
Hovorka R (2011) Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 7(7):385–395. https://doi.org/10.1038/nrendo.2011.32
Jazowski SA, Winn AN (2017) The role of the FDA and regulatory approval of new devices for diabetes care. Curr Diabetes Rep 17(6):40
Boughton CK, Hovorka R (2019) Is an artificial pancreas (closed-loop system) for type 1 diabetes effective? Diabet Med 36(3):279–286. https://doi.org/10.1111/dme.13816
Beregszàszi M, Tubiana-Rufi N, Benali K, Noël M, Bloch J, Czernichow P (1997) Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: prevalence and risk factors. J Pediatr 131(1):27–33. https://doi.org/10.1016/S0022-3476(97)70121-5
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853. https://doi.org/10.1016/S0140-6736(98)07019-6
Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572. https://doi.org/10.1056/NEJMoa0802987
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139. https://doi.org/10.1056/NEJMoa0808431
The DCCT Research Group (1991) Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90(4):450–459. https://doi.org/10.1016/0002-9343(91)80085-Z
The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the diabetes control and complications trial. Diabetes 46(2):271–286. https://doi.org/10.2337/diab.46.2.271
Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559. https://doi.org/10.1056/NEJMoa0802743
Genuth S, Ismail-Beigi F (2012) Clinical implications of the ACCORD trial. J Clin Endocrinol Metab 97(1):41–48. https://doi.org/10.1210/jc.2011-1679
Beran D, Hirsch IB, Yudkin JS (2018) Why are we failing to address the issue of access to insulin? A national and global perspective. Diabetes Care 41(6):1125–1131. https://doi.org/10.2337/dc17-2123
Rege NK, Phillips NFB, Weiss MA (2017) Development of glucose-responsive ‘smart’ insulin systems. Curr Opin Endocrinol Diabetes Obes 24(4):267–278. https://doi.org/10.1097/med.0000000000000345
Tromans RA, Carter TS, Chabanne L et al (2019) A biomimetic receptor for glucose. Nat Chem 11(1):52–56. https://doi.org/10.1038/s41557-018-0155-z
Hua QX, Nakagawa SH, Hu SQ, Jia W, Wang S, Weiss MA (2006) Toward the active conformation of insulin. Stereospecific modulation of a structural switch in the B chain. J Biol Chem 281:24900–24909. https://doi.org/10.1074/jbc.M602691200
Acknowledgements
We thank F. Ismail-Beigi (Case Western Reserve University, Cleveland, OH, USA), R. DiMarchi (Indiana University, Bloomington, IN, USA), M. D. Michael (Thermalin, Inc., Cleveland, OH, USA) and N. B. Phillips (Case Western Reserve University, Cleveland, OH, USA) for helpful discussions.
Authors’ relationships and activities
MAW is Chief Innovation Officer of Thermalin, Inc. (Waban, MA, USA) in which he has equity. All the other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
Funding
Work in the authors’ laboratories is supported by the JDRF, the Leon M. and Harry B. Helmsley Charitable Trust and NIH R01 grants DK040949 and DK127761 (to MAW).
Author information
Authors and Affiliations
Contributions
All authors conceptualised the contents, revised the article critically for important intellectual content and approved this manuscript. MAW oversaw preparation of the manuscript and wrote the first draft.
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Slideset of figures
(PPTX 2.13 mb)
Rights and permissions
About this article
Cite this article
Jarosinski, M.A., Dhayalan, B., Rege, N. et al. ‘Smart’ insulin-delivery technologies and intrinsic glucose-responsive insulin analogues. Diabetologia 64, 1016–1029 (2021). https://doi.org/10.1007/s00125-021-05422-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-021-05422-6